Drugs /

il-2 plasmid dna/lipid complex

Back to Drugs List

Overview

NCI Definition [1]:
An immunotherapeutic agent consisting of a plasmid DNA encoding human Interleukin-2 (IL-2) complexed with a cationic lipid, 1,2-dimyristyloxypropyl-3-dimethyl-hydroxyethyl ammonium bromide/dioleyl-phosphatidyl-ethanolamine (DMRIE/DOPE), in a 5:1 ratio. Due to the lipophilic nature of this cation liposome complex, this gene transfer system may improve the efficiency of introducing the IL-2 gene into the cells, thereby increasing the production of IL-2 and inducing an immune response.

Clinical Trials

View Clinical Trials for il-2 plasmid dna/lipid complex

Il-2 plasmid dna/lipid complex has been investigated in 2 clinical trials, of which 1 is open and 1 is closed. Of the trials investigating il-2 plasmid dna/lipid complex, 2 are phase 1 (1 open).

ER Negative, ER No Expression, and HER2 Deficient Expression are the most frequent biomarker inclusion criteria for il-2 plasmid dna/lipid complex clinical trials.

Anal squamous cell carcinoma, breast carcinoma, and cutaneous melanoma are the most common diseases being investigated in il-2 plasmid dna/lipid complex clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Il-2 Plasmid Dna/lipid Complex
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Il-2 Plasmid Dna/lipid Complex
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating il-2 plasmid dna/lipid complex and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
vcl-1102, interleukin-2 dna/lipid complex, plasmid dna il-2 lipid complex, il-2 plasmid dna/dmrie/dope lipid complex, plasmid dna il-2 lipid complex, il-2 plasmid dna/dmrie/dope lipid complex, leuvectin, leuvectin
Drug Target(s) [2]:
IL2RA
NCIT ID [1]:
C2437

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.